June 2015
Volume 56, Issue 7
ARVO Annual Meeting Abstract  |   June 2015
Genetic alterations in conjunctival melanoma and relation to clinical outcome
Author Affiliations & Notes
  • Nihal Kenawy
    University of Liverpool, Liverpool, United Kingdom
  • Sarah E Coupland
    University of Liverpool, Liverpool, United Kingdom
  • Bertil E Damato
    Ocular Oncology Service, University of California, San Fransisco, CA
  • Heinrich Heimann
    Liverpool Ocular Oncology Centre, Royal Liverpool University Hospital, Liverpool, United Kingdom
  • Sarah Louise Lake
    University of Liverpool, Liverpool, United Kingdom
  • Footnotes
    Commercial Relationships Nihal Kenawy, None; Sarah Coupland, None; Bertil Damato, None; Heinrich Heimann, None; Sarah Lake, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 3419. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Nihal Kenawy, Sarah E Coupland, Bertil E Damato, Heinrich Heimann, Sarah Louise Lake, Liverpool Ocular Oncology Research Group; Genetic alterations in conjunctival melanoma and relation to clinical outcome. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):3419.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: Despite improved understanding of the molecular changes in conjunctival melanoma (CoM), the underlying aetiology of this tumor remains unclear. In this study, we determined gene copy number variations (CNV) in CoM aiming to identify disease-specific genetic biomarkers to facilitate prognostication, as has been achieved in uveal melanoma.

Methods: Ninety two patients with primary CoM seen between 2005 and 2014 were recruited in eight international ocular oncology centres. Clinical and histological data were collected. DNA was extracted from paraffin-embedded samples. Fifty-nine samples yielded sufficient DNA for Affymetrix 6.0 Single Nucleotide Polymorphism (SNP) microarray testing. SNP data were analysed by Partek Genomic suite. Patients who developed regional lymph nodes and/or systemic metastases were compared to a sex, age-matched cohort of low risk clinical and pathological criteria for dissemination and with similar follow up duration.

Results: Over 40% of the samples showed amplifications of histone gene cluster (6p22.2), ETV1 (7p21.2), FOXQ1 (6p25.3 - 6p25.2) and SOX4 (6p22.3) and deletions in ASNS (7q21.3), CHEK2P2 (15q11.1), RET (10q11.21) and BAGE (21p11.1). CNVs in the two groups of metastatic CoM and the low risk comparative group were consistent. None of the chromosomes identified with gains or losses showed loss of heterozygosity or isodisomy. Based on the current median follow-up time of 2.5 years, no statistically significant correlation has been detected between any of the genetic alterations and features of poor outcome, i.e. caruncular involvement, epithelioid cell type or metastatic spread.

Conclusions: This is the largest cohort of CoM samples analysed by SNP genotyping to date and describes CNVs not previously reported. Longer follow-up is required to facilitate our understanding of CoM and identification of patients at high metastatic risk.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.